scholarly article | Q13442814 |
P2093 | author name string | Fang Liu | |
Haitao Shang | |||
Yunan Zhang | |||
Yuhu Song | |||
Qiu Zhao | |||
Xingxing He | |||
Qian Dou | |||
Jingjun Yan | |||
Junwei Yan | |||
P2860 | cites work | Global cancer statistics | Q22241238 |
p53-independent functions of the p19(ARF) tumor suppressor | Q24600863 | ||
Management of HCC | Q28258769 | ||
Tumor suppressor and hepatocellular carcinoma | Q28389231 | ||
Modes of p53 regulation | Q29615657 | ||
Management of hepatocellular carcinoma | Q29616230 | ||
p53 mutant mice that display early ageing-associated phenotypes | Q29622826 | ||
Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma | Q33711037 | ||
Mouse models of p53 functions | Q33752174 | ||
Spliceosome-mediated RNA trans-splicing | Q33990703 | ||
The role of mutant p53 in human cancer | Q34153014 | ||
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression | Q46709821 | ||
Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas | Q47417305 | ||
Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. | Q51641132 | ||
p53 — Master and Commander | Q59238393 | ||
Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing | Q64379396 | ||
20 years studying p53 functions in genetically engineered mice | Q84583331 | ||
p53 Isoforms: An Intracellular Microprocessor? | Q34202703 | ||
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally | Q34369829 | ||
Risk of HCC: genetic heterogeneity and complex genetics | Q34615016 | ||
Allele-specific p53 mutant reactivation | Q34638529 | ||
Recent advances in p53 research and cancer treatment | Q35099531 | ||
Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing | Q35928212 | ||
Mutant p53: one name, many proteins | Q36070574 | ||
Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis | Q36092123 | ||
Unleashing the power of p53: lessons from mice and men. | Q36371033 | ||
Genetic medicines: treatment strategies for hereditary disorders | Q36423907 | ||
Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells | Q36591517 | ||
p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? | Q36646572 | ||
Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 | ||
Structure-function-rescue: the diverse nature of common p53 cancer mutants | Q36777367 | ||
Reactivation of mutant p53: molecular mechanisms and therapeutic potential | Q36777373 | ||
Modulating the expression of disease genes with RNA-based therapy. | Q36866549 | ||
Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts | Q37230210 | ||
Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis | Q37295226 | ||
Molecular mechanisms of hepatocellular carcinoma | Q37323726 | ||
30 years and a long way into p53 research | Q37589207 | ||
p53-based cancer therapy | Q37750115 | ||
Translating p53 into the clinic. | Q37803120 | ||
p53 mutations in cancer | Q38069463 | ||
ARF tumor suppression in the nucleolus | Q38187767 | ||
An algorithm for finding protein-DNA binding sites with applications to chromatin-immunoprecipitation microarray experiments | Q38287394 | ||
β-2 spectrin is involved in hepatocyte proliferation through the interaction of TGFβ/Smad and PI3K/AKT signalling | Q39357385 | ||
MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo | Q39447513 | ||
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. | Q39966300 | ||
Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. | Q40528526 | ||
Mouse models to study the interaction of risk factors for human liver cancer. | Q40547714 | ||
Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing | Q40906944 | ||
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer | Q45066172 | ||
Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma | Q45858736 | ||
Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing | Q45863479 | ||
Chinese gene therapy. Splicing out the West? | Q45864019 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatocellular carcinoma | Q1148337 |
P304 | page(s) | 8705 | |
P577 | publication date | 2015-03-03 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo | |
P478 | volume | 5 |
Q64240589 | Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma |
Q38845711 | CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo |
Q42491454 | Can we be SMaRT-er in our approach to cancer therapy? |
Q35947493 | Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL. |
Q28078238 | Differential Impacts of Alternative Splicing Networks on Apoptosis |
Q51745116 | Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. |
Q50958336 | Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. |
Q36557358 | MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. |
Q26799788 | Mouse models of liver cancer: Progress and recommendations |
Q41585790 | NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity |
Q92890849 | Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells |
Q55387849 | Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA. |
Q26750650 | mRNA trans-splicing in gene therapy for genetic diseases |
Q51738169 | β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin. |
Search more.